Overview
| Name | TamGen · aliases: TamGen |
|---|---|
| Full name | The paper uses the model name only; no expanded name |
| Ambiguous names (not auto-linked) | None |
| Family | Not a family entry. A single model with no family members or successor |
| Organization | Microsoft Research AI for Science, Global Health Drug Discovery Institute (GHDDI) |
| Organization type | Mixed |
| Country | China, United States |
| Model class | Target-conditioned molecule generation (chemical language model + pocket encoder) |
| Domain | Small molecules (also: Molecule generation) |
| First release | · paper revision Basis: Preprint posted (registry record) Note: Previously recorded as 2024-01 (month only); upgraded to day precision from the registry record source |
| Other milestones | |
| Latest update | † partly verified · journal Basis: Journal publication Journal publication is the latest sourced substantive event; the repository has no releases and its last commit (2025-09-24) is maintenance whose content was not inspected Note: Maintenance commits post-date the journal event, but the policy on counting maintenance commits is unsettled, so this is flagged unverified source The most recent sourced event, not a claim that nothing changed since. |
| Status | Maintained only · Maintenance commits only, the last on 2025-09-24 |
| Openness | Code: Open Weights: Unclear Code is open under the developer's GitHub organisation; licence text and weights release were not retrieved this round |
| Benchmarks reported | 1 counted (self 1) |
| Wet-lab validation | 1 recorded campaign |
| Unverified fields | † latest_update, open_status.weights, open_status.code_license, wetlab_validation[0].affinity_best |
| As of | 2026-11-16 |
What it does
Adds a protein-pocket context encoder to a chemical language model for target-conditioned generation and refinement of existing molecules; the paper runs a full design-refine-test loop, with the big-lab side generating compounds and a nonprofit drug-research institute doing binding analysis, structure-activity work and enzyme assays. Unlike GenMol and Saturn it closes a real wet-lab loop but does not compete on public optimisation suites.
Benchmarks reported
Every row is one pairing from the survey's relation file; a score belongs to the benchmark page's ranking, where it is shown with metric, eval set, source type and date. 1 of 1 pairings are counted.
| Benchmark | Relation | Eval set / protocol | Source type | Note and evidence |
|---|---|---|---|---|
| 32 CrossDocked2020 | Developer report, official protocol | — | Self-reported | Self-reported on the 100 test pockets, with values in the supplement †partly verified · evidence |
Other evaluations (outside the 44)
- Own metric combination for target-conditioned generation (Own task set) Self-reported: The paper aggregates drug-likeness and docking metrics with a mean reciprocal rank; that aggregation is not an official protocol
- Viral target case (Case study) Self-reported: The developer page also mentions a coronavirus target; a case description without evaluation data
Developers report: target-conditioned generation plus refinement yields compounds that can go straight to assay, and ranks near the top on several drug-likeness and docking metrics on a public pocket set.
Independent evidence: No independent evidence found. No third-party evaluation or replication found; assays were run by the partner institute and compiled by the authors
Training data
Group in Figure 7: Public data + wet lab for validation only.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Yes | Decoder pretrained on 10 million SMILES sampled from a public compound library; target conditioning trained on CrossDocked2020 and similar complex sets source |
| b. Private or licensed data | No | source |
| c. Own wet-lab data used for training | No | No claim of feeding assay results back into training source |
| d. Wet lab used only for validation | Yes | In-vitro enzyme inhibition against one tuberculosis protease target, used for validation only source |
Wet-lab validation
Every rate carries its numerator and denominator. Claims that could not be verified are shown as unverified, without numbers; different paper versions are separate entries.
Denominator basis: 2,612 / 8,635 designs generated with 296 selected onward; the 14 active compounds comprise 5 commercial analogues, 3 structure-activity syntheses, and 6 of 8 directly synthesised compounds (in-vitro inhibition below the 40 μM level)
No overall success rate: the hits span three different sources (commercial analogues, SAR syntheses, direct syntheses) and cannot be merged into one ratio; the published "16 tested" claim does not exist in the paper and is removed
Executor: Assays run by the partner nonprofit drug-research institute; not an independent evaluation
Background
- Organization: A science-AI research division of a US software company (founded 2022) together with a nonprofit drug-discovery institute founded in Beijing in 2016 by a global-health foundation, the Beijing government and a Chinese university; co-authors also come from two Chinese universities.
- Funding: The nonprofit institute received about $100M of five-year support initially, and in 2023-06 the foundation announced a further $50M over five years with municipal matching; the paper states partial support from that foundation.
- Products and partnerships: The two organisations announced a collaboration in 2024-01: the big-tech lab generates candidates and the institute runs the experiments, with stated plans for lead optimisation, ADMET improvement and preclinical work; terms undisclosed.
- Related models: GenMol, Saturn
Reading notes
- The 14 actives are not 14 model-generated molecules: five are commercial analogues and three are structure-activity syntheses, and the most potent one is a commercial analogue.
- The real denominators are 2,612 / 8,635 designs with 296 selected; the site's earlier "16 tested" is not in the paper.
- In-vitro enzyme inhibition is early hit-level evidence; no cell or animal data, so it is far from a drug.
- On CrossDocked the per-metric values live in a figure and the supplement with none in the main text, so cross-paper comparison needs care.
Caveats
- Wet-lab hits span three source types and cannot be merged into a single success rate.
- The latest-update framing depends on the unsettled maintenance-commit policy and is flagged unverified.
- The site said there was no site-benchmark pairing; one self-reported pairing on the official protocol does exist.
- The aggregate ranking method is the authors' own, not the benchmark's official protocol.
Sources
- Journal paper 2024 (journal)
- Journal full text (public archive) (journal)
- Preprint registry record (preprint)
- Code repository (repository)
- Developer research blog (company blog)
Corrections
3 corrections
| Field | Was | Now | Basis | Found |
|---|---|---|---|---|
| wetlab_validation | 16 compounds tested, 14 strong inhibitors, best IC50 1.88 μM | Removed "16 tested" (the paper does not say so); the 14 actives are 5 commercial analogues + 3 SAR syntheses + 6 of 8 direct syntheses, and the most potent is a commercial analogue; 2,612/8,635 designed, 296 selected | source | 2026-11-16 |
| first_release | 2024-01 | 2024-01-08 (preprint posted) | source | 2026-11-16 |
| benchmarks_reported | No pairing with a benchmark on this site | CrossDocked: self-reported on the official protocol | source | 2026-11-16 |
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.